System and method for controlling ventricular pacing during AF based on underlying ventricular rates using an implantable medical device

• US 8,340,765 B2
• Filed: 03/24/2009
• Issued: 12/25/2012
• Est. Priority Date: 03/24/2009
• Status: Active Grant

• Current Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Original Assignee: Pacesetter Incorporated (Abbott Laboratories Incorporated)
• Inventors: Boileau, Peter, Benser, Michael E.
• Primary Examiner(s): Getzow, Scott
• Assistant Examiner(s): PATTON, AMANDA K
• Application Number:
  US12/410,386
• Publication Number:
  US 20100249862A1
• Time in Patent Office: 1,372 Days
• Field of Search: 607/14, 607/9
• US Class Current: 607/14
• CPC Class Codes: A61N 1/3622 comprising two or more electrodes co-operating with different heart regions
• CPC Class Codes: A61N 1/3702 Physiological parameters A61N1/365 takes precedence; evoked response A61N1/371

Abstract

Techniques are provided for controlling ventricular pacing during an episode of atrial fibrillation (AF) for use by a pacemaker, implantable cardioverter-defibrillator (ICD) or other implantable medical device. In one example, upon detection of AF, the underlying intrinsic ventricular rate of the patient is determined prior to delivering any ventricular pacing. Then, a ventricular pacing procedure—such as dynamic ventricular overdrive (DVO) pacing—is activated to reduce ventricular rate variability to mitigate the adverse effects of AF. The ventricular pacing procedure employed during AF is controlled based on a maximum ventricular rate set relative to the underlying intrinsic ventricular rate so as to keep an overall ventricular rate below the maximum rate.

Claims

1. A method for use by an implantable medical device equipped to selectively deliver pacing therapy to the ventricles during atrial fibrillation (AF), comprising:

inputting a maximum ventricular rate increase;

detecting AF within the heart of a patient in which the device is implanted;

determining an underlying intrinsic ventricular rate during AF; and

delivering ventricular pacing therapy during AF at a ventricular rate not exceeding a maximum rate set based on the underlying intrinsic ventricular rate and the maximum rate increase.

2. The method of claim 1 wherein delivering ventricular pacing therapy during AF is performed to maintain an overall ventricular rate representative of both paced beats and intrinsic beats below the maximum rate.

3. The method of claim 1 wherein the maximum rate increase is a user-specified value initially received from an external programmer device.

4. The method of claim 1 wherein the maximum rate increase is determined by the implantable device.

5. The method of claim 1 wherein determining the underlying intrinsic ventricular rate during AF includes:

detecting ventricular intrinsic beats prior to activation of ventricular pacing during AF; and

determining the underlying intrinsic ventricular rate based on the intrinsic beats detected prior to the activation of ventricular pacing.

6. The method of claim 5 wherein detecting ventricular intrinsic beats prior to activation of ventricular pacing during AF is performed for a period of time in the range of 3 to 120 seconds.

7. The method of claim 1 wherein determining the underlying intrinsic ventricular rate during AF includes:

temporarily suspending any on-going ventricular pacing delivered during AF; and

determining the underlying intrinsic ventricular rate based on intrinsic beats detected during the suspension of ventricular pacing.

8. The method of claim 7 wherein temporarily suspending ventricular pacing during AF is performed for one of:

a predetermined number of pacing cycles or a predetermined number of seconds.

9. The method of claim 7 wherein temporarily suspending ventricular pacing during AF is performed periodically.

10. The method of claim 7 wherein the underlying intrinsic ventricular rate is determined during AF based on trends derived from previously-detected underlying intrinsic ventricular rates.

11. The method of claim 10 wherein the underlying intrinsic ventricular rate is determined during AF based on a moving average derived from previously-detected underlying intrinsic ventricular rates.

12. The method of claim 1 wherein the device is equipped to deliver pacing in a ventricular-triggered pacing mode and wherein determining the underlying intrinsic ventricular rate includes:

temporarily switching to the ventricular-triggered pacing mode; and

determining the underlying intrinsic ventricular rate during AF based on intrinsic beats detected during ventricular-triggered pacing.

13. The method of claim 1 wherein delivering ventricular pacing therapy during AF at a ventricular rate not exceeding the maximum rate is achieved by selectively adjusting parameters affecting the ventricular pacing rate used by the implantable device.

14. The method of claim 13 wherein the implantable device is equipped to deliver dynamic ventricular overdrive (DVO) pacing and wherein selectively adjusting parameters affecting the ventricular pacing rate during AF includes selectively adjusting one or more DVO control parameters.

15. The method of claim 1 wherein the maximum rate is set equal to the underlying intrinsic ventricular rate plus the maximum rate increase.

16. A system for use with an implantable medical device equipped to selectively deliver pacing therapy to the ventricles, comprising:

an atrial fibrillation (AF) detection unit;

an AF-based underlying intrinsic ventricular rate determination unit; and

an AF-responsive ventricular pacing controller operative during AF to deliver ventricular pacing at a ventricular rate not exceeding a maximum rate set based on the underlying intrinsic ventricular rate and a maximum rate increase.

17. The system of claim 16 wherein the AF-responsive ventricular pacing controller is operative to maintain an overall ventricular rate representative of both paced beats and intrinsic beats below the maximum rate.

18. The system of claim 16 wherein the AF-responsive ventricular pacing controller includes an underlying intrinsic ventricular rate (VR_UNDERLYING)-based ventricular pacing rate limiter operative to limit the ventricular rate during AF to a maximum ventricular rate (VR_MAX) set based on VR_UNDERLYING and a maximum rate increase (VR_MAX-INCREASE).

19. A system for use with an implantable medical device equipped to selectively deliver pacing therapy to the ventricles during an episode of atrial fibrillation (AF), comprising:

means for detecting AF;

means for determining an underlying intrinsic ventricular rate during AF; and

means for delivering ventricular pacing therapy during AF at a ventricular rate not exceeding a maximum rate set based on the underlying intrinsic ventricular rate and a maximum rate increase.

20. The system of claim 19 wherein the means delivering ventricular pacing therapy during AF is operative to maintain an overall ventricular rate representative of both paced beats and intrinsic beats below the maximum rate.